

# Index

- abdominal examinations 67
- abdominal massage 143–4
- abdominal pain 32–3
- abdominoperineal resection 283
- Abrams-Griffiths (AG) number 208
- absorbent pads 86
- absorbent products, for urinary incontinence 86
- ACC *see* anterior cingulate cortex (ACC)
- ACEs (antegrade continence enemas) 148, 262
- acetylcholine (ACh) 27  
mediation 2–3  
release 1, 3, 101
- ACh *see* acetylcholine (ACh)
- acquired neuropathies 278–80
- ACT (adjustable continence therapy) 121–2
- acute demyelinating encephalomyelitis (ADEM) 235  
and bladder disturbances 67
- acute hemispheric stroke, and urinary disorders 179
- acute idiopathic autonomic neuropathy 281–2
- acute inflammatory demyelinating polyneuropathy (AIDP) 280–1
- acute intermittent porphyria (AIP) 287–8
- acute motor axonal neuropathy (AMAN) 280–1
- acute stroke, and urinary incontinence 179
- ADEM *see* acute demyelinating encephalomyelitis (ADEM)
- adenosine triphosphate (ATP) 2–3  
release 3
- adherens junctions 2–3
- adjustable continence therapy (ACT) 121–2
- afferent axons, types of 1
- afferent nerve endings, in bladder 1
- afferent nerves 89
- afferent pathways 19  
changes 5–7
- afferent signals, and bowel function 31–2
- AG (Abrams-Griffiths) number 208
- AIDP (acute inflammatory demyelinating polyneuropathy) 280–1
- AIP (acute intermittent porphyria) 287–8
- alimentary tract *see* gut
- $\alpha$ -adrenergic blockers 211
- $\alpha$ -adrenoreceptor agonists 250–1, 301–2
- $\alpha$ -adrenoreceptor antagonists (ARs)  
applications 96  
mechanisms 95–6  
in neurogenic detrusor overactivity treatment 95–6
- $\alpha$ -adrenoreceptors 161  
stimulation 1–2, 4
- alprostadil  
efficacy 160  
in erectile dysfunction treatment 160  
side-effects 160
- altered sexuality 44
- Alzheimer's disease (AD)  
and detrusor overactivity 92  
and urinary incontinence 180
- AMAN (acute motor axonal neuropathy) 280–1
- American Spinal Injury Association (ASIA) 128  
classification system 241
- amezinium 212
- amitriptyline 232
- amygdala  
and Kluver-Bucy syndrome 44  
roles 44  
and sexual functions 44–5
- amyloid neuropathy 278  
*see also* familial amyloid polyneuropathy (FAP)
- anal resting pressure (RP) 34
- anal sphincter complex 25, 27  
*see also* external anal sphincter (EAS); internal anal sphincter (IAS)
- anal sphincter dysfunction, symptoms 127
- anal sphincter motor units, neurogenic changes 209
- anal squeeze pressure (SQ) 34
- aneurysms, anterior cerebral artery 175
- angina 159
- animal studies  
ejaculation 52–3  
hypersexuality 172–3  
Kluver-Bucy syndrome 172–3  
medial pre-optic area 198  
sexual behavior, and subcortical lesions 176  
sexual responses 40  
cortical studies 42  
subcortical studies 42
- anismus 191–2, 212, 214  
use of term 191
- ankylosing spondylitis, and cauda equina syndrome 271–2
- anorectal digitation 136
- anorectal investigations 135
- anorectal manometry  
and bowel dysfunction 34–5  
eight-channel 34  
methodology 34  
in neurogenic bowel dysfunction management 140–1  
sensation testing 34

- anorectal physiology 135  
tests 128, 135
- anorectal videomanometry  
multiple system atrophy 215  
Parkinson's disease 191, 215  
studies 190–1
- ansa lenticularis 176–7  
roles 176
- ANS (autonomic nervous system),  
functions 27
- antegrade colonic washouts 262
- antegrade continence enemas  
(ACEs) 148, 262
- anterior cerebral artery, aneurysms 175
- anterior cingulate cortex (ACC)  
roles 13–14  
rostral 31–2  
*see also* dorsal anterior cingulate  
cortex (dACC)
- anticholinergics 301–2  
precautions 197
- antidepressants 232
- antidiarrheal agents 146
- antimuscarinics  
applications 74, 82, 197  
classification 93  
clinical efficacy 90–2  
reviews 90  
diffusion 93  
efficacy 224  
high-dose studies 92–3  
licensed, in United Kingdom 90, 92  
mechanisms 89–90  
in multiple sclerosis 92, 224–5  
in neurogenic detrusor overactivity  
treatment 89–95  
efficacy 92–3  
in neurological patients 93  
in overactive bladder treatment  
90–60, 259–60  
in Parkinson's disease 94  
recommendations 94–5  
side-effects 90–1, 93–4, 224–5  
targets 90  
trials 90–1  
randomized controlled 91–2  
and urinary retention 90  
usage algorithm 224
- antiparkinsonian drugs 200
- APHRODITE trial 161
- apomorphine 191–2  
applications 231  
efficacy 159, 231
- penile erection induction 43  
side-effects 200
- arthritis 269–70
- Arizona Sexual Experience Scale  
(ASEX) 280
- ARs *see*  $\alpha$ -adrenoreceptor  
antagonists (ARs)
- artificial urinary sphincter (AUS) 122
- ASEX (Arizona Sexual Experience  
Scale) 280
- asexuality, and temporal lobe  
epilepsy 173
- Asexual Visibility and Education  
Network (AVEN) 173
- ASIA *see* American Spinal Injury  
Association (ASIA)
- Aspidosperma quebracho-blanco*  
(herb) 161
- astrocytomas 270–1
- ATP *see* adenosine triphosphate  
(ATP)
- audiovisual sexual stimulation  
(AVSS) 180
- A $\delta$ -fibers 1  
roles 11
- augmentation cystoplasty *see* bladder  
augmentation
- AUS (artificial urinary sphincter) 122
- autoimmune autonomic  
ganglionopathy 282
- autonomic disorders, and multiple  
system atrophy 210
- autonomic dysfunction 280–1  
and Lambert-Eaton myasthenic  
syndrome 288
- autonomic dysreflexia 144–5  
and bowel dysfunction 33  
mechanisms 243  
severity factors 243  
and spinal cord injury 242–3  
symptoms 243  
treatment 243
- autonomic failure, use of term  
210–11
- autonomic function  
assessment 241  
classification 128
- autonomic nerves  
damage, and pelvic surgery 281, 282  
and neuromuscular disorders 278
- autonomic nervous system (ANS),  
functions 27
- AVEN (Asexual Visibility and  
Education Network) 173
- AVSS (audiovisual sexual  
stimulation) 180
- axons  
afferent 1  
nerve 3–5  
preganglionic, types of 28
- B12 deficiency 235
- back pain  
and cauda equina syndrome 272  
chronic 270–1  
severe 270
- baclofen 104  
applications 232
- Barrington's nucleus 11–12, 189  
roles, in defecation 30–1
- Barthel Index 179–80
- behavioral retraining, for neurogenic  
bladder dysfunctions 79
- Bell-Magendie law 266
- benign prostatic hyperplasia  
(BPH) 120  
hormone-mediated models of 96  
and Parkinson's disease 192
- benzodiazepines 301–2
- $\beta$ -adrenoreceptor agonists  
clinical efficacy 96  
mechanisms 96  
in neurogenic detrusor overactivity  
treatment 96  
side-effects 96
- $\beta$ -adrenoreceptors  
activation 2–3, 10  
stimulation 1–2, 4
- bethanechol test 210
- biofeedback  
in neurogenic bowel dysfunction  
management 147, 262  
pelvic floor therapy 81
- bisacodyl suppositories 145
- bladder  
afferent nerve endings 1  
roles 2  
aging 8  
autonomous hyperactive 273  
bivalved 118  
brain control of, concepts 11  
and brain lesions 177–8  
and cerebrovascular disease 178–9

## Index

- bladder (cont.)  
 changing patterns, and multiple system atrophy 210  
 cortical control of 167  
 decentralized 273, 294–5  
 and focal frontal lesions 167–71  
 full, peak activation areas 13  
 functional brain imaging studies 12  
 and head injuries 182  
 immunohistochemical staining 1, 6  
 low compliance 177–8  
 management 221  
 neurological control of 1–9  
 neuropathic 246  
 obstructed 8  
 post-void residual volume 82  
 pressure flow studies 70–1  
 retraining 222  
 and subcortical lesions 176  
 superficial layers 90  
 transverse section 102  
 urinary control 196
- bladder augmentation 117–18  
 and spinal cord injury 248–9
- bladder augmentation  
 enterocystoplasty 117–18  
 applications 117  
 follow-up 118  
 future trends 118  
 results 118  
 surgical techniques 117–18  
 selection criteria 117
- bladder cancer 123  
 follow-up reviews 227  
 and multiple sclerosis 227  
 and spinal cord injury 246
- bladder capacity, increasing 89
- bladder control  
 in Parkinson's disease, brain structures 195  
 and prefrontal cortex 14–15
- bladder decentralization, and detrusor overactivity 73
- bladder diaries 65, 66–7, 243  
 in nocturnal polyuria 282  
 twenty-four hours 62
- bladder diseases, and changes in peripheral control of micturition 5–9
- bladder disturbances  
 etiology 67  
 physical examination 67
- bladder dysfunctions 210–11, 235  
 and cauda equina syndrome 273–4  
 and cerebrovascular disease 178–9  
 and diabetes mellitus 279  
 differential diagnoses 67–9  
 and familial amyloid polyneuropathy 286–7  
 and frontal tumors 170–1  
 and hysterectomy 282–3  
 and multiple sclerosis 221–7  
 containment 227  
 general measures 222  
 infections 227  
 investigations 223  
 management 222  
 other measures 224  
 pathophysiology 221  
 physical treatments 222  
 surgical treatments 226–7  
 symptoms 221–2  
 and multiple system atrophy 206–12  
 management 211–12  
 pharmacotherapy 211–12  
 and muscular dystrophies 288  
 and neurological diseases, correlation 193  
 and Parkinson's disease 192–8  
 and pelvic nerve injury 282  
 physical examination 67  
 and pure autonomic failure 282  
 and residual urine 82  
 and spina bifida 256  
 and spinal cord injury 241–9  
 treatment 247  
 in suprasacral injuries 247  
 treatment 10  
*see also* neurogenic bladder dysfunctions; overactive bladder (OAB)
- bladder emptying *see* bladder voiding
- bladder filling 298–300  
 and cerebellum 177  
 cystometry 70–1  
 disturbances 89  
 functional brain imaging 16–17  
 interoception 300  
 and medial prefrontal cortex 16  
 and urge incontinence 14  
 urodynamics 70–1  
 videourodynamics 65
- bladder function  
 flow rate 197–8  
 normal, cellular signaling pathways 2–5  
 residual volume 197–8  
 spinal control of 9–11
- bladder neck, and multiple system atrophy 208
- bladder pain syndrome (BPS) 8
- bladder pathophysiology  
 lesion literature for 168  
 and spinal reflexes 10
- bladder scans 64, 69
- bladder sensation, and interoception 12–14
- bladder stones 123  
 and spinal cord injury 244
- bladder storage  
 $\alpha$ -adrenoreceptor antagonists and 96  
 disturbances 89  
 impaired, treatment 224–6  
 and multiple system atrophy 207  
*see also* urine storage
- bladder surgery, in multiple sclerosis 226–7
- bladder symptoms  
 and multiple sclerosis 221–2  
 and multiple system atrophy 206  
 in Parkinson's disease  
 future treatments 198  
 investigations 196–7  
 management 196–7  
 pathophysiology 194–5  
 pharmacotherapy 197  
 prevalence 193  
 treatment 195–6  
 and spinal cord injury 242–3
- bladder-to-bladder excitatory reflex 9–10
- bladder-to-external urethral sphincter excitatory reflex 10
- bladder-to-urethral sphincter inhibitory reflex 9–10
- bladder urothelium, roles 3–5
- bladder voiding 13–14, 61, 298–300  
 and cauda equina syndrome 273  
 cystometry 70–1  
 incomplete 294  
 mechanisms 208  
 and multiple system atrophy 208, 209  
 and spinal cord injury 242  
 non-invasive aids 82  
 strategies 82  
 treatment 249  
 urodynamics 70–1
- bladder wall, ultrastructural components 5
- bladder-sacral spinal cord-bladder reflex 10–11
- bladder-sphincter-bladder reflex 10

- $\alpha$ -blockers 104
  - applications 224
- blood tests
  - for neurogenic bladder dysfunctions 68
  - for sexual dysfunction 156
- blood-brain barrier, drug penetration 94
- BoNT/A *see* botulinum neurotoxins (BoNTs); type A (BoNT/A)
- BoNT/B (botulinum neurotoxin type B) 100
- BoNTs *see* botulinum neurotoxins (BoNTs)
- Botox *see* botulinum neurotoxins (BoNTs)
- botulinum neurotoxins (BoNTs) 9
  - applications 74, 192, 211
  - detrusor injections 198, 225, 248
  - intravesical injections 100–3
    - applications 101–2
    - clinical efficacy 103
    - clinical studies 100–1
    - commercial formulations 100
    - mechanisms 100
    - procedures 102–3
    - recommendations 103
  - type A (BoNT/A) 99
    - detrusor injections 75, 221, 225–6
    - efficacy 260
    - intradetrusor injections, in spina bifida 258, 260
    - intravesical injections 7, 100–3
      - for sphincter 104
  - type B (BoNT/B) 100
  - and urinary tract infections 102–3
- bowel
  - anatomy 25
  - autonomic innervation 28
  - and brain lesions 178
  - and cerebrovascular disease 179–80
  - and focal frontal lesions 171
  - neurological control of 25–36
    - in health 25–6
    - pathophysiology 228
    - and subcortical lesions 176
- bowel dysfunction
  - and anorectal manometry 34–5
  - and autonomic dysreflexia 33
  - and brain lesions 178
  - and cauda equina syndrome 274
  - and dementia 181
  - and familial amyloid polyneuropathy 287
  - future research 36
  - and Guillain-Barre syndrome 281
  - lesion literature for 169
  - and multiple sclerosis 228–30
    - assessment 229
    - management algorithm 229
    - prevalence 228, 229–30
    - treatment 229
  - and multiple system atrophy 212–14
    - management 214
    - mechanisms 212
    - over time 33
    - and Parkinson's disease 187–92
      - prevalence 25, 187
      - and spina bifida 256, 261–2
        - assessment 261
        - treatment 261–2
      - and spinal cord injury 32, 249–50
      - and stroke 179–80
      - symptoms 25
      - see also* neurogenic bowel dysfunction (NBD)
- bowel dysmotility 288
- bowel function
  - and afferent signals 31–2
  - cerebral control 30
  - effects of neurological diseases on 32–6
  - and efferent signals 32
  - neuroimaging 30–1
  - regulatory mechanisms 188–9
  - in spinal cord injury, outcome measures 128, 134
  - studies 128
  - see also* international bowel function spinal cord injury data sets
- bowel management programs 138–9
  - conservative pre-emptive 142–3
  - construction 146–7
  - development 139
  - lifestyle goals 140
  - medical history 139
  - prior assessment 139–40
    - physical examinations 140
  - strategies 230
- bowel symptoms
  - and multiple system atrophy 212–13
  - prevalence
    - and multiple system atrophy 213
    - in Parkinson's disease 189
- bowel wall
  - anatomy 25
  - innervation 26
- BPH *see* benign prostatic hyperplasia (BPH)
- BPS (bladder pain syndrome) 8
- brain activity patterns
  - orgasm 50
  - sexual stimulation 4
- brain control, of bladder, concepts 11
- brain lesions 167
  - and bladder 177–8
  - and bowel 178
  - and bowel dysfunction 178
  - computed tomography scans 178
  - magnetic resonance imaging 178
  - see also* focal frontal lesions; subcortical lesions
- brain pathways
  - in defecation control 31
  - in gut control 31
- brainstem, and sexual functions 50
- brainstem lesions 177–8
  - and urinary symptoms 177–8
  - for voiding dysfunction 177
- brain structures
  - bladder control, in Parkinson's disease 195
  - see also* anterior cingulate cortex (ACC); cerebellum; frontal lobes; hypothalamus; parietal lobe; prefrontal cortex; temporal lobes
- brain tumors
  - and urinary symptoms 171
  - and voiding dysfunction 177
- brain-bladder control networks 16–19
  - circuits 16
    - mechanical 16
    - safety 16–17
    - social 17–19
- breast cancer 161
- Brindley root stimulators 266
  - implantation 266
- Bristol nomogram 70
- Bristol Stool Form Scale 139–40, 142, 143, 145, 146
- bromocriptine 195–6
- bulbocavernosus reflex *see* penilobulbocavernosus reflex
- bulking agents 122
- cabergoline 200
- cadherin-11, expression 8
- CADT (Compound Autonomic Dysfunction Test) 286–7
- calcitonin gene-related peptide (CGRP) 6
  - occurrence 3

## Index

- calcium channel antagonists 301–2
- calcium polycarboxophil 214
- cAMP (cyclic adenosine monophosphate), hydrolysis 158–9
- Campylobacter jejuni* (bacterium) 280
- cancer  
breast 161  
prostate 193  
*see also* bladder cancer; tumors
- cannabidiol (CBD), applications 225
- cannabinoid (CB) agonists  
applications 225  
clinical efficacy 97  
mechanisms 97  
in neurogenic detrusor overactivity treatment 97  
trials 97
- capsaicin 6, 97  
clinical efficacy 99  
intravesical 225  
mechanisms 98  
natural sources of 98
- carbamazepine 232
- care in the community, and neurogenic bowel dysfunction management 138–9
- catheterization  
intermittent 82–3  
urethral 83–4  
*see also* clean intermittent self catheterization (CISC); indwelling catheterization; suprapubic catheterization
- catheters  
blockage 123  
duration of use 84  
early 84  
intermittent 83  
selection criteria 84  
self-retaining 84  
*see also* indwelling catheters (IDCs); suprapubic catheters (SPCs)
- catheter valves 85
- cauda equina  
compression 267  
acute 272  
magnetic resonance imaging 269  
development 266  
dorsal nerve roots 266  
neural structures 267  
structure 266  
ventral nerve roots 266
- cauda equina damage  
epidemiology 266–70  
etiology 266–70  
incidence 266–7  
pelvic organ dysfunction after 266  
prevalence 266–7
- cauda equina syndrome (CES)  
acute  
etiology 267–70  
investigations 274  
motor and sensory symptoms 270–1  
and ankylosing spondylitis 271–2  
and bladder dysfunctions 273–4  
and bladder voiding 273  
and bowel dysfunction 274  
and central neuraxial block 269–70  
chronic  
etiology 270–1  
investigations 274  
motor and sensory symptoms 272–4  
and chronic neuropathic pain syndromes 275  
clean intermittent self-catheterization in 275  
co-morbidities 270–1  
and constipation 272, 275  
and detrusor overactivity 273  
diagnostic issues 272  
early interventions 274–5  
epidemiology 266–70  
etiology 266–70  
drug side-effects 270  
and fecal incontinence 275  
incidence 269  
investigations 274  
management 274–5  
peer support 275  
medicolegal issues 275  
motor innervation 266, 267  
and overactive bladder 273–4  
and pelvic organ dysfunction 272–3  
postoperative hematomas 267–9  
and sensory loss 272  
and sexual dysfunction 274  
management 275  
and spinal canal stenosis 271  
and spinal fracture 267  
and tuberculosis 271  
and urinary incontinence 273  
and urinary retention 272, 273  
and urinary symptoms 273–4
- CB1 receptors 3
- CB2 receptors 3
- CB agonists *see* cannabinoid (CB) agonists
- CBD (cannabidiol), applications 225
- CCK (cholecystokinin), roles 29
- cell junctions, roles 8
- cellular signaling pathways, in normal bladder function 2–5
- central control, of lower urinary tract function 19
- central nervous system (CNS)  
control, dysfunction 36  
roles, in defecation 30–1
- central neuraxial block, and cauda equina syndrome 269–70
- central pontine myelinolysis 235
- cerebellum 177  
and bladder filling 177  
and detrusor overactivity 177  
and micturition 12, 177  
and multiple system atrophy 177
- cerebral control  
of bowel function 30  
micturition 171
- cerebrovascular disease 178–80  
and bladder 178–9  
and bladder dysfunctions 178–9  
and bowel 179–80  
and constipation 180  
and sexual behavior 180  
and urinary retention 179
- CES *see* cauda equina syndrome (CES)
- C-fiber afferents 3
- C-fibers 1  
excitation 5–6  
roles 11
- cGMP *see* cyclic guanosine monophosphate (cGMP)
- CGRP *see* calcitonin gene-related peptide (CGRP)
- Charcot-Marie-Tooth disease 287
- Chiari II malformation 256
- chilli peppers, capsaicin 98
- cholecystokinin (CCK), roles 29
- cholinergic pathway, changes 7–8
- chronic idiopathic pseudo-obstruction (CIPO) 295
- chronic inflammatory demyelinating neuropathy (CIDP) 280
- chronic neuropathic pain syndromes, and cauda equina syndrome 275

- chronic urinary retention  
management 303–5  
sacral neuromodulation 303–5
- Cialis *see* tadalafil
- CIDP (chronic inflammatory demyelinating neuropathy) 280
- CIPO (chronic idiopathic pseudo-obstruction) 295
- cisapride, applications 33, 192
- CISC *see* clean intermittent self-catheterization (CISC)
- c-Kit, expression 188–9
- clam cystoplasty *see* bladder augmentation
- clean intermittent self-catheterization (CISC) 89, 208, 225–6  
advantages 82  
and antimuscarinics 74, 82  
applications 73–4, 82, 103, 249  
in cauda equina syndrome 275  
concept of 82  
females 82  
neurological patients and 82–3  
selection criteria 83  
in suprasacral spinal cord injury  
bladder dysfunction  
management 248  
in urinary retention management 297–8  
in voiding dysfunction management 82–4, 223–4, 259
- Cleveland Constipation Score 128
- clitoris  
anatomy 56  
dorsal nerve 54, 73  
innervation of 55  
vacuum devices 161
- CNEs *see* concentric needle electrodes (CNEs)
- CNS *see* central nervous system (CNS)
- Cochrane reviews 92
- cognitive ability, and neurogenic bowel dysfunction 140
- cognitive impairment  
and depression 94  
and muscarinic receptor inhibition 94
- collagen beads 122
- colon, functions 25
- colonic activity 29  
contractile 29  
control 29  
disturbances 30
- colonic transit time (CTT) 128, 134–5  
delayed 33  
mean 33  
measurement 33  
in multiple system atrophy 213, 214  
in Parkinson's disease, studies 190  
radiographical determination 135
- colonmetrograms 35–6
- colonoscopy 136
- colorectal dysfunction, symptoms 127
- colorectal transit time *see* colonic transit time (CTT)
- compliance 35–6  
curves 35  
definition 35  
measurement 35–6  
and spinal cord injury 36
- Compound Autonomic Dysfunction Test (CADT) 286–7
- computed tomography (CT) scans  
brain  
lesions 178  
pituitary adenomas 174  
*see also* single photon emission computed tomography (SPECT)
- concentric needle electrodes (CNEs) 72  
advantages 72–3
- Consortium for Spinal Cord Medicine, guidelines 243
- constipation 32, 36, 178  
and cauda equina syndrome 272, 275  
and cerebrovascular disease 180  
definitions 32  
and dementia with Lewy bodies 181  
management, algorithms 310  
and multiple sclerosis 228  
and neurogenic bowel dysfunction 136  
and Parkinson's disease 187, 189  
pharmacotherapy 191  
post-stroke patients 179–80  
prevalence 32, 138  
and spinal cord injury 32  
treatment 288  
*see also* fecal incontinence (FI)
- continence  
appliances to aid 85–7  
factors affecting 1  
maintenance 26  
therapy, adjustable 121–2  
*see also* incontinence
- corpus cavernosum  
electromyography 156
- cortical control, of bladder 167
- cortical disorders 167–82
- cortical inputs  
to human sexual cycle 42–3  
animal studies 42
- cortical representation, of penis 45–6
- cough pressure 34
- counseling, for sexual dysfunction 162
- Credé's maneuver 82, 224, 246, 249
- CT scans *see* computed tomography (CT) scans
- CTT *see* colonic transit time (CTT)
- cutaneous continent diversions 119  
applications 119  
follow-up 119  
Mitrofanoff procedure 119  
results 119  
surgical techniques 119  
Yang-Monti procedure 119
- cutaneous urinary diversions 119–20
- cyclic adenosine monophosphate (cAMP), hydrolysis 158–9
- cyclic guanosine monophosphate (cGMP)  
hydrolysis 158–9  
inhibitors 275  
in penile erection 41, 159
- cystectomy  
and sexual dysfunction 283  
subtrigonal 118
- cystograms, with voiding phase 243–4, 246,
- cystometry 70–1, 197–8, 223, 298  
and detrusor overactivity 65  
procedures 70
- cytochrome P450, metabolism 93
- Cytomegalovirus* 280
- D2 receptors 43
- D3 receptors 43
- dACC *see* dorsal anterior cingulate cortex (dACC)
- Dai-Kenchu-To 214
- dantrolene 104
- darifenacin 197  
diffusion 93  
muscarinic receptor selectivity 93
- defecation 30  
control, brain pathways 31

## Index

- defecation (cont.)  
 factors affecting 30  
 and high amplitude propagated contractions 30  
 impaired 214  
 and spinal cord injury 36  
 and straining 30, 191
- defecation scintigraphy 134–5
- delta-9-tetrahydrocannabinol (THC), applications 225
- dementia 180–1  
 and bowel dysfunction 181  
 and sexual behavior 181  
 and toileting 181  
 and urinary incontinence 180
- dementia with Lewy bodies (DLB) 197  
 and constipation 181  
 and urinary incontinence 180
- depression  
 and cognitive impairment 94  
 and sexual dysfunction 158
- dermatomes 266  
 sacral 268
- desmopressin 74  
 applications 212  
 clinical efficacy 95  
 mechanisms 95  
 in neurogenic detrusor overactivity treatment 95  
 in nocturia treatment 95, 225  
 in polyuria treatment 247  
 in postural hypotension treatment 212  
 side-effects 95
- detrusor areflexia 177–8, 179
- detrusor hyperreflexia 177–8, 179
- detrusor muscle 2–3  
 relaxation 4
- detrusor myectomy 117  
 development 117  
 results 117  
 surgical technique 117
- detrusor overactivity (DO) 5–8, 62  
 $\alpha$ -adrenoreceptor antagonists in 96  
 and Alzheimer's disease 92  
 and bladder decentralization 73  
 and cauda equina syndrome 273  
 and cerebellum 177  
 cystometry 65  
 etiology 7–8  
 and multiple sclerosis 221  
 treatment 224–6  
 and multiple system atrophy 206–8  
 and Parkinson's disease 194–5  
 pelvic floor muscle training 80  
 pharmacotherapy 91, 96, 195–6  
 and suprapubic vibrators 224  
 therapeutic electrical stimulation 81  
 treatment 6–7, 10, 211  
*see also* idiopathic detrusor overactivity (IDO); neurogenic detrusor overactivity (NDO)
- detrusor pressure, estimation 70
- detrusor smooth muscle 1
- detrusor sphincter dyssynergia (DSD) 179, 246  
 and multiple sclerosis 221  
 and multiple system atrophy 208  
 pharmacotherapy 104, 249  
 sacral neuromodulation in 114  
 and spinal cord injury 242  
 symptoms 65  
 treatment 249
- detrusor underactivity 8–9
- detumescence, mechanisms 41
- Devic's disease 235
- diabetes mellitus 278–80  
 and bladder dysfunctions 279  
 and diarrhea 280  
 and erectile dysfunction 160, 279–80  
 and fecal incontinence 280  
 and gastrointestinal tract dysfunction 280  
 and lower urinary tract dysfunction 278  
 neuropathies, classification 278  
 and peripheral neuropathy 278  
 and sexual dysfunction 280  
 type 1 278  
 type 2 278  
 urodynamics 279
- diabetic cystopathy  
 management 279  
 pathophysiology 278–9  
 use of term 278
- diabetic neuropathies, classification 278, 279
- diagnostic shadowing 67
- Diagnostic and Statistical Manual-IV (DSM-IV), sexual satisfaction algorithm 280
- diarrhea 36  
 and diabetes mellitus 280
- diet, and neurogenic bowel dysfunction management 143
- dietary fiber 191
- digital evacuation, of feces 144–5
- digital rectal examinations 67
- digital rectal stimulation 144–5
- dimethylmercaptosuccinic acid (DMSA) renography 243
- diphenhydramine, and oxybutynin compared 94
- diplopia, horizontal 175
- dipstick urinalysis 227  
 in urinary tract infections 63, 67–8, 223
- diversions  
 cutaneous urinary 119–20  
 urinary 227  
*see also* cutaneous continent diversions
- DLB *see* dementia with Lewy bodies (DLB)
- DMD (Duchenne muscular dystrophy) 288
- DMSA (dimethylmercaptosuccinic acid) renography 243
- DO *see* detrusor overactivity (DO)
- docusate enemas 145–6
- domperidone, applications 191–2
- donepezil 181
- dopamine 176–7  
 applications 191–2  
 roles 188–9, 200
- dopamine agonists 159, 176–7, 200  
 applications 231  
 studies 43
- dopamine dysregulation syndrome, and Parkinson's disease 200
- dopaminergic blockers 191–2
- dopaminergic pathways, loss of 198
- dopamine transporters, studies 193
- dorsal anterior cingulate cortex (dACC) 13–14  
 roles 31–2  
 and social circuit 17–19
- DSD *see* detrusor sphincter dyssynergia (DSD)
- DSM-IV (Diagnostic and Statistical Manual-IV), sexual satisfaction algorithm 280
- dual-hit theory 187

- Duchenne muscular dystrophy (DMD) 288
- Duloxetine, in sphincter functional improvement 104
- dysraphic disturbances 256
- EAS *see* external anal sphincter (EAS)
- EAU (European Association of Urology), guidelines 94–5, 258
- ED *see* erectile dysfunction (ED)
- EDSS *see* expanded disability status scale (EDSS)
- efferent nervous system *see* enteric nervous system (ENS)
- efferent parasympathetic nerves 1
- efferent signals, and bowel function 32
- eGFR *see* estimated glomerular filtration rate (eGFR)
- ejaculation  
 animal studies 52–3  
 phases 41  
 and spinal cord injury 250–1  
 vibro-ejaculation 250–1  
*see also* electroejaculation
- ejaculation dysfunction, treatment 161, 232
- ejaculator generators 52
- electrical stimulation, in neurogenic bladder dysfunction treatment 112–15
- electrodes  
 St Mark's 73  
*see also* concentric needle electrodes (CNEs)
- electroejaculation 52  
 procedure 161
- electromyography (EMG)  
 biofeedback 81  
 corpus cavernosum 156  
 definition 72  
 in Fowler's syndrome investigations 295–7  
 in neurogenic bladder dysfunction investigations 72–3  
 procedures 72–3  
 technical issues 72  
 urethral sphincter 298  
*see also* sphincter electromyography
- EMG *see* electromyography (EMG)
- endorphins, release 41
- enemas 145–6
- administration 145–6
- antegrade continence 148, 262
- docusate 145–6
- efficacy 146
- mechanisms 145–6
- ENS *see* enteric nervous system (ENS)
- enteric nervous system (ENS)  
 anatomy 26–7  
 myenteric plexus 27  
 neurons 26–7  
 neuropeptides 27  
 and Parkinson's disease 189  
 submucosal plexus 27
- enteric neurons, classification 27
- enterocystoplasty 118
- enteropathy, visceral 295
- ependymomas 270–1
- epilepsy 45  
 and sexual dysfunction 45  
 temporal lobectomy 173  
*see also* temporal lobe epilepsy (TLE)
- Epsstein-Barr virus 280
- erectile dysfunction (ED) 153, 176  
 and diabetes mellitus 160, 279–80  
 evaluation 155  
 and multiple sclerosis 160, 230–1  
 and multiple system atrophy 217  
 and Parkinson's disease 198  
 pelvic floor therapy 160–1  
 risk factors 156  
 and spinal cord injury 160, 250  
 and stroke 180  
 treatment 158–61, 217, 231–2, 261  
 first-line 158–60  
 second-line 160–1
- erection (penile) *see* penile erection
- EROS-CTD system 161, 162, 232
- esthesiometers 157
- estimated glomerular filtration rate (eGFR)  
 applications 68  
 procedures 68
- estrogen, assays 156
- Euphorbia resiniferae* (cactus), resiniferatoxin 98
- European Association of Urology (EAU), guidelines 94–5, 258
- evacuation  
 digital 144–5  
 and neurological diseases 34–5
- evacuation disorders 32  
 categorization 32
- Everaert, K. 114
- expanded disability status scale (EDSS)  
 applications 220  
 levels 220
- external anal sphincter (EAS)  
 anatomy 26  
 functions 26
- external sphincter dyssynergia  
*see* detrusor sphincter dyssynergia (DSD)
- external urethral sphincter 210
- extrinsic nervous system, functions 27
- familial amyloid polyneuropathy (FAP) 286–7  
 and bladder dysfunctions 286–7  
 and bowel dysfunction 287  
 etiology 286  
 symptoms 286–7  
 uroflow curves 287
- familial dysautonomia (FD) 287  
 classification 287
- FAP *see* familial amyloid polyneuropathy (FAP)
- FD *see* familial dysautonomia (FD)
- fecal impaction  
 assessment 67  
 fecal loading 142  
 incidence 141  
 management 141  
 studies 142  
 and physically disabled 142  
 symptoms 141–2
- Fecal Incontinence and Constipation Quality of Life (FIC QOL) questionnaire 261
- fecal incontinence (FI) 32  
 and cauda equina syndrome 275  
 definition 32  
 and diabetes mellitus 280  
 management, algorithms 311  
 and multiple sclerosis 229  
 prevalence 32, 138  
 and quality of life 128  
 and recto-anal inhibitory reflex 35  
 scores 128  
 and spina bifida 257, 261  
 treatment 262  
 and stroke 180  
 and tethered cord syndrome 263  
*see also* constipation
- fecal peritonitis 83–4



## Index

- feces  
 consistency 191  
 differentiation 35  
 digital evacuation 144–5  
*see also* Bristol Stool Form Scale
- female genital innervation 55–6
- females  
 clean intermittent self  
   catheterization 82  
 Fowler's syndrome 301–2  
   urethral pressure profile 298  
 indwelling catheters 84  
 orgasm  
   brain activations 50  
   education 232  
   studies 52  
 orgasmic dysfunction 162  
   treatment 161  
 pelvic floor therapy, physical  
   examinations 80  
 sexual activity 40  
 urge incontinence 17  
 urinary retention 17, 295, 297
- female sexual dysfunction (FSD)  
 and multiple sclerosis 232  
 and multiple system atrophy 217  
 pathophysiology 231  
 prevalence 153  
 secondary and tertiary sources 232  
 and spinal cord injury 251–2  
 treatment 232  
 treatment options 161–3, 232
- Female Sexual Function Index (FSFI)  
 156, 231, 316
- female sexual responses 41
- Ferticare vibrator 250–1
- fertility, and spinal cord injury 251
- fetal surgery, in spina bifida 257
- fetishisms 173–4
- FI *see* fecal incontinence (FI)
- FIC QOL (Fecal Incontinence and  
 Constipation Quality of Life)  
 questionnaire 261
- fir trees, use of term 246
- flatus 140–1  
 and diet 143  
 differentiation 35  
 incontinence of 274
- Florida pouch 119
- fluid intake, and overactive  
 bladder 79, 222
- fMRI *see* functional magnetic  
 resonance imaging (fMRI)
- focal frontal lesions 167–72  
 and bladder 167–71  
 and bowel 171  
 and sexual behavior 172
- Foley, Frederic 84
- folic acid  
 metabolism 255  
 roles 255–6  
 supplementation 255–6
- forebrain activation, of spinal  
 reflexes 43
- Fowler's syndrome (FS) 8–9, 17,  
 295–7  
 clinical features 297–8  
 diagnosis 295  
 electromyography 295–7  
 females 301–2  
   urethral pressure profile 298  
 functional magnetic resonance  
   imaging 299  
 investigations 297–8  
 symptoms 297
- frequency 6–7  
*see also* urinary frequency
- frequency/voiding charts 79
- frontal lobes  
 pathology, and micturition 167–71  
 and sexual functions 45
- frontal lobe tumors  
 and bladder dysfunctions 170–1  
 and urinary incontinence 171
- FS *see* Fowler's syndrome (FS)
- FSD *see* female sexual  
 dysfunction (FSD)
- FSFI (Female Sexual Function Index)  
 156, 231, 316
- Fukuyama, H. 12
- functional brain imaging  
 bladder filling 16–17  
 bladder studies 12  
 of orgasm 49–50  
 of post-ejaculation 50  
 of sexual activity 46–50  
 of sexual desire 47  
 of sexual excitement 47–9  
 urethra studies 12
- functional magnetic resonance imaging  
 (fMRI)  
 applications 15  
 and bladder filling 16–17  
 in Fowler's syndrome 299
- GABA ( $\gamma$ -amino butyric acid) 27
- gastric emptying, mechanisms 33
- gastrin, roles 29
- gastrocolic reflex 30, 143  
 and gut motility 33–4  
 mechanisms 33–4
- gastrointestinal hormones 29
- gastrointestinal physiology 25
- gastrointestinal (GI) tract  
 anatomy 25  
*see also* lower gastrointestinal tract
- gastrointestinal tract dysfunction,  
 and diabetes mellitus 280
- GBS *see* Guillain-Barre syndrome (GBS)
- GCI *see* glial cytoplasmic inclusions  
 (GCIs)
- genital automatism 45, 173–4  
 use of term 172
- genitalia, innervation 51
- genital prolapse 162
- genital sensation  
 forebrain activation of spinal reflexes  
   43  
 impaired 156–7
- GI tract *see* gastrointestinal  
 (GI) tract
- glans clitoridis 55–6  
*see also* clitoris
- glans penis 54  
*see also* penis
- glial cytoplasmic inclusions (GCIs)  
 constituents 206  
 in multiple system atrophy 206
- globus pallidus 176–7  
 roles 176
- glycerin suppositories 145
- gonadal hormones  
 receptors 44  
 roles 43
- Groupe d'études de neuro-urologie de  
 langue française 222
- guarding reflex 1, 4, 10  
 roles 9
- Guillain-Barre syndrome (GBS)  
 278, 280–1  
 and bowel dysfunction 281  
 incidence 280  
 and infections 280  
 symptoms 280
- gut  
 control, brain pathways 31  
 motility, and gastrocolic reflex 33–4

- physiology, in neurological diseases 33–6  
reflexes 30
- HAPCs *see* high amplitude propagated contractions (HAPCs)
- head injuries 181–2  
and bladder 182  
and sexual behavior 181–2
- health care professional, roles 235
- hematomas, postoperative, in cauda equina syndrome 267–9
- hematuria  
bleeding sites 65  
definition 65  
etiology 65  
and lower urinary tract dysfunction 65  
urine cytology 68
- hemiparesis 179
- hemispherical asymmetry, sexual drive 45
- hemorrhoids 136
- high amplitude propagated contractions (HAPCs) 29  
and defecation 30
- Hirschsprung's disease 29–30
- HIV infection, and neuromuscular disorders 283
- Hoehn and Yahr staging 189, 193, 194, 200
- home environment, assessment 140
- Honolulu Heart Program 187
- horizontal diplopia 175
- hormone replacement therapy (HRT), and hypoactive sexual desire disorder 161
- hormones  
gastrointestinal 29  
*see also* gonadal hormones
- HRT (hormone replacement therapy), and hypoactive sexual desire disorder 161
- HSDD *see* hypoactive sexual desire disorder (HSDD)
- 5-HT *see* serotonin (5-HT)
- human sexual cycle  
cortical inputs 42–3  
human data 42–3  
neuroendocrine effects 43–4  
phases 40  
subcortical inputs 42–3  
human data 42–3  
triphasic model 40
- human sexual responses  
cycle, neural inputs 42  
neurology 40
- hydrocephalus, and urinary incontinence 171
- hyperglycemia 280
- hyperprolactinemia 156, 176  
and multiple system atrophy 217  
and Parkinson's disease 198
- hyperreflexia 257
- hypersexuality 43, 172, 200  
animal studies 172–3  
assessment 156  
and Parkinson's disease 176–7  
and temporal lobe resection 173
- hypoactive sexual desire disorder (HSDD) 40  
and hormone replacement therapy 161  
use of term 161
- hypogonadism 156, 176
- hyponatremia 95
- hyposexuality, and temporal lobe epilepsy 44–5, 173
- hypotension 159  
*see also* orthostatic hypotension; postural hypotension
- hypothalamic lesions 176
- hypothalamus  
brain imaging 174  
roles, in sexual drive 42  
and subcortical lesions 174–5
- hypothyroidism 156
- hysterectomy 282–3  
and bladder dysfunctions 282–3  
pelvic organ nerve damage 55  
and sexual dysfunction 283
- IAS *see* internal anal sphincter (IAS)
- IBS (irritable bowel syndrome) 36
- ICCs *see* interstitial cells of Cajal (ICCs)
- ICI (International Consultation on Incontinence) 100, 103
- IC (interstitial cystitis) 8
- IDCs *see* indwelling catheters (IDCs)
- idiopathic detrusor overactivity (IDO) 9  
mechanisms 14–15  
neural plasticity in 9
- IDO *see* idiopathic detrusor overactivity (IDO)
- IFSF (Index of Female Sexual Function) 280
- IIEF (International Index for Erectile Function) 156, 180, 231, 314
- ileal conduits 119–20  
in multiple sclerosis management 120  
results 120  
surgical techniques 119–20
- imaging  
neuroimaging 30–1  
*see also* computed tomography (CT) scans; functional brain imaging; magnetic resonance imaging (MRI); positron emission tomography (PET)
- Implantable Pulse Generator (IPG) 114
- impulse control disorders, and Parkinson's disease 200
- incontinence 6–7  
of flatus 274  
functional vs. neurogenic 179  
location of lesions causing 15  
social issues 17–18  
*see also* fecal incontinence (FI); urinary incontinence
- Incontinence Impact Questionnaire 312
- incontinence pads 87
- Incontinence Quality of Life Instrument 66
- Index of Female Sexual Function (IFSF) 280
- indoramin, trials 104
- indwelling catheterization  
disadvantages 83  
routes 83–4  
in voiding dysfunction management 83, 224
- indwelling catheters (IDCs) 84  
functions 83  
lengths 84  
limitations 122  
in multiple sclerosis 224  
risk factors 83–4  
self-retaining 84  
types of 83–4  
and urinary diversion 227  
and urinary tract infections 83–4  
urine drainage bags 84–5
- infections  
HIV 283  
lower urinary 227

## Index

- infections (cont.)  
 in multiple sclerosis, bladder dysfunctions 227  
 urinary 271  
*see also* urinary tract infections (UTIs)
- infertility treatment 161
- infrasacral lesions, in spinal cord injury 242
- inherited neuropathies 286–8
- Innsbruck approach 257–8
- insula activation, and urine storage 13
- intermittent catheterization 82–3  
*see also* clean intermittent self-catheterization (CISC)
- intermittent catheters 83
- internal anal sphincter (IAS)  
 anatomy 26  
 functions 26
- internal urethral sphincter, and multiple system atrophy 208
- international bowel function spinal cord injury data sets 128–34  
 basic 129  
 creation 133–4  
 development 128  
 extended 131  
 items 128–33
- International Consultation on Incontinence (ICI) 100, 103
- International Continence Society 13–14, 103  
 classification 65  
 recommendations, questionnaires 66
- International Index for Erectile Function (IIEF) 156, 180, 231, 314
- International Prostate Symptom Score (IPSS) 194, 66, 312–14  
 applications 193
- International Spinal Cord Society (ISCoS) 128,
- International Standards for the Neurological Classification of Spinal Cord Injury 128
- interneurons  
 roles 10, 27  
 spinal, functions 10
- interoception, and bladder sensation 12–14
- Interstim 113, 114
- interstitial cells of Cajal (ICCs) 25, 188–9  
 roles 29
- interstitial cystitis (IC) 8
- intervertebral disc protrusion 270
- intestinal dysmotility 175–6
- intestinal pseudo-obstruction (paralytic ileus),  
 incidence 189
- intra-abdominal gastrointestinal tract, anatomy 25
- intravesical agents, in neurogenic detrusor overactivity  
 treatment 248
- intravesical atropine  
 clinical efficacy 100  
 mechanisms 99–100  
 in neurogenic detrusor overactivity  
 treatment 99–100
- intravesical electrostimulation 112–13  
 applications 112–13  
 mechanisms 112  
 procedures 112
- intravesical lidocaine 98  
 clinical efficacy 100  
 mechanisms 99–100  
 in neurogenic detrusor overactivity  
 treatment 99–100
- intravesical nociceptin/orphanin FQ 98  
 clinical efficacy 100  
 mechanisms 99–100  
 in neurogenic detrusor overactivity  
 treatment 99–100
- intravesical oxybutynin 98  
 clinical efficacy 100  
 mechanisms 99–100  
 in neurogenic detrusor overactivity  
 treatment 99–100
- intravesical treatments  
 development 97–8  
 of neurogenic detrusor overactivity 97–8  
 rationales 98  
 recommendations 100
- intravesical vanilloids 98  
 clinical efficacy 98–9  
 mechanisms 98  
 natural sources of 98  
 in neurogenic detrusor overactivity  
 treatment 98–9, 248  
 recommendations 100  
 safety 98–9
- intrinsic afferents 27
- intrinsic nervous system *see* enteric nervous system (ENS)
- intrinsic primary afferent neurons (IPANs) 188–9
- IPANs (intrinsic primary afferent neurons) 188–9
- IPG (Implantable Pulse Generator) 114
- IPSS *see* International Prostate Symptom Score (IPSS)
- irritable bowel syndrome (IBS) 36
- ISCoS (International Spinal Cord Society) 128
- isotope renography 69
- Japanese pelvic organ questionnaire 193, 195
- KBS *see* Kluver-Bucy syndrome (KBS)
- kidney stones, and spinal cord injury 244
- Kleine-Levin syndrome 43
- Kluver-Bucy syndrome (KBS) 44  
 altered sexuality 44  
 amygdala and 44  
 animal studies 172–3
- labia separation, appliances 83
- Lambert-Eaton myasthenic syndrome (LEMS), and autonomic dysfunction 288
- LAPCs (low amplitude phasic contractions) 29
- large intestine, roles 25
- laxatives 146  
 types of 146
- L-DOPA *see* levodopa
- leg abduction, appliances 83
- LEMS (Lambert-Eaton myasthenic syndrome), and autonomic dysfunction 288
- lesion literature  
 for bladder pathophysiology 168  
 for bowel dysfunction 169  
 for sexual dysfunction 169  
 use of term 167
- leucodystrophies 235
- leucotomy 170–1
- Levitra *see* vardenafil
- levodopa  
 absorption 191  
 applications 191–2, 200
- levosulpiride 191–2
- Lewy bodies 188, 189, 282

- formation 188–9  
*see also* dementia with Lewy bodies (DLB)
- Lewy body dementia *see* dementia with Lewy bodies (DLB)
- libidinous temporal lobes 172
- libido  
 definition 40–1  
 loss of 43, 176, 180
- lidocaine 8, 99  
*see also* intravesical lidocaine
- lifestyle goals, in bowel management programs 140
- long-loop spinobulbospinal reflex 11
- loperamide 146
- low-amplitude phasic contractions (LAPCs) 29
- lower gastrointestinal tract  
 function tests 190–1  
 symptoms  
   in myasthenia 287–8  
   in Parkinson's disease 189
- lower lumbar spine injury, and penile erection 52
- lower motor neuron lesions,  
 concept of 294
- lower urinary infections 227
- lower urinary tract  
 behavior 11  
 morphological damage 246  
 roles 61
- lower urinary tract dysfunction (LUTD)  
 approaches 73  
 multidisciplinary 74–6  
 bladder diaries 66–7  
 classification 62, 61  
 and diabetes mellitus 278  
 diagnostic evaluation 75  
 etiology 62, 61  
 evaluation 61  
   algorithms 307–8  
 guidelines 258  
 and hematuria 65  
 history 61–2  
 management 66, 73–4  
   algorithms 307–8  
   goals 63  
   multidisciplinary team approach 75  
   step-wise approach 75  
 and multiple sclerosis 221  
 and nocturia 63
- quality of life 66  
 specialist investigations 69  
 storage symptoms 62  
 symptoms 61  
 symptom scales 66  
 and urinary incontinence 63  
 urodynamics 69–71  
 videourodynamics 71–2  
 and voiding symptoms 65
- lower urinary tract function  
 central control of 19  
 preservation 258
- lower urinary tract symptoms (LUTS) 62–5, 192  
 bladder diaries 66–7  
 cannabinoid agonists in 97, 225  
 definitions 64  
 etiology 64  
 history 61–2  
 multifunctional 62  
 in multiple system atrophy 217  
 questionnaires 66
- L-region 12
- lumbar discs, herniation 267
- LUTD *see* lower urinary tract dysfunction (LUTD)
- LUTS *see* lower urinary tract symptoms (LUTS)
- Madersbacher classification 258
- MAG3 (mercaptoacetyltriglycine) renography 243
- magnetic resonance imaging (MRI)  
 brain lesions 178  
 cauda equina compression 269  
 pituitary adenomas 174  
 rhombencephalitis 175  
*see also* functional magnetic resonance imaging (fMRI)
- male genital innervation 53–4
- males  
 aging, prostate disease 192  
 indwelling catheters 84  
 orgasm  
   brain activations 50  
   mechanisms 41  
 pelvic floor 26  
 pelvic floor therapy, physical examinations 80  
 urinary incontinence appliances 86  
 urinary retention 295
- male sexual dysfunction  
 pathophysiology 230–1  
 prevalence 153  
 secondary and tertiary sources 232  
 and spinal cord injury 250–1  
 treatment options 158–61, 231–2
- male sexual responses 41
- Massachusetts Male Aging Study 279–80
- massage, abdominal 143–4
- maximum urethral closure pressure (MUCP) 298, 300
- MD (myotonic dystrophy) 288
- MDRD (Modification of Diet in Renal Disease) 68
- medial prefrontal cortex, and bladder filling 16
- medial pre-optic area (MPOA) 42  
 animal studies 198  
 roles, in sexual drive 42
- mercaptoacetyltriglycine (MAG3) renography 243
- metoclopramide 191–2  
 applications 33
- micturition  
 and cerebellum 12, 177  
 cerebral control 171  
 and frontal lobe pathology 167–71  
 pathways 2, 11  
 peripheral control of 1–2  
   changes in bladder disease states 5–9
- micturition reflex 194
- midodrine 161, 212
- mid-stream urine (MSU) test 68
- Miller Fisher syndrome 280
- mirabegron, in detrusor overactivity treatment 96
- mitochondrial cytopathy 288
- mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) 288
- Mitrofanoff procedure 119, 262
- MNGIE (mitochondrial neurogastrointestinal encephalomyopathy) 288
- Modification of Diet in Renal Disease (MDRD) 68
- modified Rome criteria 32
- molecular mimicry 280
- monoamine oxidase inhibitors 161
- mosapride, applications 192

## Index

- motor disorders, and multiple system atrophy 210
- motor innervation, in cauda equina syndrome 266, 267
- motor neurons  
excitatory 27  
inhibitory 27
- mouthcecum transit time  
mean 33  
prolongation 33
- Movicol 142
- MPOA *see* medial pre-optic area (MPOA)
- MRI *see* magnetic resonance imaging (MRI)
- MRIcro 47
- MS *see* multiple sclerosis (MS)
- MSA *see* multiple system atrophy (MSA)
- MSU (mid-stream urine) test 68
- MUCP (maximum urethral closure pressure) 298, 300
- multiple sclerosis (MS) 220–35  
antimuscarinics in 92  
and bladder cancer 227  
and bladder disturbances 67  
and bladder dysfunctions 221–7  
containment 227  
general measures 222  
infections 227  
investigations 223  
management 222  
other measures 224  
pathophysiology 221  
physical treatments 222  
surgical treatments 226–7  
symptoms 221–2  
bladder surgery 226–7  
and bladder symptoms 221–2  
botulinum neurotoxin injections 225  
and bowel dysfunction 228–30  
assessment 229  
management algorithm 229  
prevalence 228, 229–30  
treatment 229  
cannabinoid agonists in 97  
characterization 220  
and constipation 228  
and detrusor overactivity 221  
treatment 224–6  
and detrusor sphincter dyssynergia 221  
disease progression, measurement 220  
and erectile dysfunction 160, 230–1  
and fecal incontinence 229  
and female sexual dysfunction 232  
ileal conduit management 120  
and lower urinary tract dysfunction 221  
and neurogenic detrusor overactivity, other measures 225  
and nocturnal polyuria 225  
prevalence 25, 220  
primary 220  
progressive relapsing 220  
relapses, and infections 227  
relapsing remitting 220  
sacral neuromodulation in 114, 226  
secondary progressive 220  
and sexual dysfunction 230–5  
diagnosis 231  
disability 231  
healthcare professional roles 235  
investigations 231  
multifactorial causes 230  
pathophysiology 230–1  
prevalence 230  
treatment 230, 231–2  
subtypes 220  
upper urinary tract complications, risk factors 223  
and urinary incontinence 221  
urine testing 223  
urodynamics 70–1, 223  
and voiding dysfunction, management 223–4
- multiple system atrophy (MSA) 159, 206–17  
anorectal videomanometry 215  
and autonomic disorders 210  
and bladder dysfunctions 206–12  
management 211–12  
pharmacotherapy 211–12  
and bladder storage 207  
and bladder symptoms 206  
and bowel dysfunction 212–14  
management 214  
mechanisms 212  
and bowel symptoms 212–13  
prevalence 213  
cerebellar dysfunction subtype (MSA-C) 206  
differential diagnosis 206  
and cerebellum 177  
colonic transit time 213, 214  
and detrusor overactivity 206–8  
and detrusor sphincter dyssynergia 208  
diagnosis 206  
differential 294  
and erectile dysfunction 217  
and incomplete bladder voiding 208, 209  
lower urinary tract symptoms 217  
and motor disorders 210  
and orthostatic hypotension 217  
parkinsonian subtype (MSA-P) 206  
differential diagnosis 206, 210–11  
and Parkinson's disease, differential diagnosis 193  
and quality of life 206  
and sexual dysfunction 214–17  
females 217  
management 217  
and sexual symptoms 214–17  
sphincter electromyography, neurogenic changes 209–10  
and sphincter weakness 213–14  
and urinary symptoms 206, 211  
prevalence 212  
surveys 212  
voiding symptoms 208
- muscarinic acetylcholine receptors  
roles 2–3  
subtypes 2–3
- muscarinic receptors 3  
expression 89–90  
inhibition, and cognitive impairment 94  
localization 90, 95  
M1 93  
M2 89–90, 93  
M3 89–90, 93  
selectivity 93  
roles 90, 93
- muscle disorders 288
- muscular dystrophies 288  
and bladder dysfunctions 288
- myasthenia, lower gastrointestinal tract symptoms in 287–8
- Mycoplasma pneumoniae* (bacterium) 280
- myelopathies  
non-compressive 235  
urodynamics 233, 235
- myenteric plexus 26, 27
- myofibroblasts, roles 3–5
- myotomes 266, 267
- myotonia 295–7
- myotonic dystrophy (MD) 288
- naftopidil, applications 211
- National Health and Social Life Survey (US) 153

- National Hospital for Neurology and Neurosurgery (UK) 303
- National Patient Safety Agency (NPSA) (UK) 83–4  
Reporting and Learning System 122
- National Service Framework (UK) 68
- natural killer (NK) cells, activation 5
- NBD *see* neurogenic bowel dysfunction (NBD)
- NDO *see* neurogenic detrusor overactivity (NDO)
- neostigmine, applications 33–4
- nerve axons, roles 3–5
- nerve growth factor (NGF)  
axonal transport deficiency 278–9  
expression 3
- nerves  
afferent 89  
efferent parasympathetic 1  
*see also* autonomic nerves
- nervous system  
autonomic 27  
extrinsic 27  
*see also* central nervous system (CNS); enteric nervous system (ENS)
- Netherlands Pharmacovigilance Foundation 301–2
- neural control, of pelvic organs 167
- neural groove, defective closure 255
- neural plasticity, in idiopathic detrusor overactivity 9
- neural tube  
closure 255  
etiology 255  
mechanisms 255
- neuroendocrine disorders, and temporal lobe epilepsy 45
- neuroendocrine effects, in human sexual cycle 43–4
- neurogenic bladder dysfunctions  
approaches 61–76  
non-pharmacological 79–87  
behavioral retraining 79  
blood tests 68  
comorbidities 61  
differential diagnoses 67–9  
electrical stimulation 112–15  
electromyography 72–3  
evaluation 61–76  
and fluid intake 79
- general measures 79–87  
investigations 67–9  
specialist 69  
management, algorithms 307  
pelvic floor treatments 79–81  
pharmacotherapy 89–104  
physical examination 67  
and spina bifida 257  
surgical treatments 112–23  
goals 112  
indications 112  
selection criteria 112  
symptom scales 66–7  
treatment 247–9  
options 112  
urodynamics 69–71  
uro-neurophysiology 72–3  
videourodynamics 71–2  
*see also* lower urinary tract dysfunction (LUTD)
- neurogenic bowel dysfunction (NBD)  
anorectal physiology 135  
approaches 127–36  
and cognitive ability 140  
co-morbidities 138, 139  
and constipation 136  
etiology 141  
evaluations 127–8  
algorithms 309  
physical 136  
investigations 134–5  
management 138–49  
algorithms 309  
and care in the community 138–9  
clinical assessment 139–40  
conservative pre-emptive 142–3  
diet and 143  
future trends 149  
investigational assessment 140–1  
routines 143  
specific 142–3  
surgical interventions 148–9  
*see also* bowel management programs  
prevalence 127  
and quality of life 138–9, 149  
risk factors 138  
scores 128  
and spinal cord injury 138, 139  
symptom-based scores 128  
symptoms 127
- Neurogenic Bowel Dysfunction Score 139–40, 319
- neurogenic claudication 271
- neurogenic detrusor overactivity (NDO) 7  
and multiple sclerosis, other measures 225  
pharmacotherapy 89–103, 247
- $\alpha$ -adrenoreceptor antagonists 95–6  
antimuscarinics 89–95  
desmopressin 95  
forthcoming 96–7  
intravesical 97–8  
in spina bifida, botulinum neurotoxin type A intradetrusor injections 260  
and spinal cord injury 243–4, 245  
treatment 247–9
- neurogenic sexual dysfunction  
evaluation 153–63  
management 153–63
- neuroimaging, bowel function 30–1
- neurological bladder dysfunctions  
*see* neurogenic bladder dysfunctions
- neurological control  
of bladder 1–9  
of bowel 25–36  
in health 25–6  
of sexual functions 40–56
- neurological diseases  
and bladder dysfunctions, correlation 193  
bowel symptoms in 32–3  
effects on bowel function 32–6  
and evacuation 34–5  
gut physiology in 33–6
- neurological disorders, sexual dysfunction in 153–4
- neurological dysfunction, and urinary retention 293–5
- neurological patients  
antimuscarinics in 93  
and clean intermittent self-catheterization 82–3
- neurology  
human sexual responses 40  
sexual functions 56
- neuromuscular disorders 278–88  
and HIV infection 283  
and pelvic organ dysfunction 278  
*see also* neuropathies
- neuromuscular junction, disorders 288
- neurons  
enteric 27  
in enteric nervous system 26–7  
intrinsic primary afferent 188–9  
*see also* interneurons; motor neurons
- neuropathies 278–81  
acquired 278–80  
diabetic 278, 279  
inherited 286–8

## Index

- neuropeptides  
in enteric nervous system 27  
interactions, with neurotransmitters 5
- neurosyphilis 283–4
- neurotransmitters  
in erection 159  
interactions, with neuropeptides 5
- neurulation  
primary 255  
secondary 255
- Newton, A. 30
- NGF *see* nerve growth factor (NGF)
- nicotinic receptors 3
- nifedipine 243
- nitrates 159
- nitric oxide donors 104
- nitric oxide (NO) 27  
in penile erection 41  
release, in sexual stimulation 159  
roles 41
- NK (natural killer) cells, activation 5
- NMSQuest *see* Non-motor Symptoms Questionnaire (NMSQuest)
- NO *see* nitric oxide (NO)
- nocturia  
desmopressin treatment 95, 225  
etiology 63  
evaluation, formulae 65  
and lower urinary tract dysfunction 63  
and Parkinson's disease 195, 197  
pathophysiology 65, 6–7  
and pure autonomic failure 282  
studies 195–6  
urgency 62
- nocturnal polyuria 212  
bladder diaries 282  
and multiple sclerosis 225  
symptoms 63
- nomograms 70
- Non-motor Symptoms Questionnaire (NMSQuest) 193, 195  
applications 193
- non-steroidal anti-inflammatory drugs (NSAIDs) 301–2
- noradrenaline *see* norepinephrine
- norepinephrine 27  
effects on bladder 1–2
- nPGi (nucleus paragigantocellularis), roles 42
- NPSA *see* National Patient Safety Agency (NPSA) (UK)
- NSAIDs (non-steroidal anti-inflammatory drugs) 301–2
- nucleus paragigantocellularis (nPGi), roles 42
- nucleus pulposus, herniation 267
- OAB *see* overactive bladder (OAB)
- ON *see* Onuf's nucleus (ON)
- Onuf-Onufrowicz, Bronislaw 209
- Onuf's nucleus (ON) 10, 11, 26, 189, 209, 212  
somatic efferents 4, 1
- opiates  
urinary retention studies 303  
and voiding dysfunction 301–3
- organomegaly 67
- orgasm  
females  
brain activations 50  
education 232  
and spinal cord injury 251  
studies 52  
functional brain imaging 49–50  
induced 176  
males  
brain activations 50  
mechanisms 41
- orgasmic auras 173–4
- orgasmic dysfunction  
females 162  
treatment 161  
females 161
- orthostatic hypotension 210–11  
and multiple system atrophy 217
- overactive bladder (OAB) 9  
antimuscarinic treatment 259–60  
trials 90–1  
approaches, non-pharmacological 79–87  
and cauda equina syndrome 273–4  
general measures 79–87  
immunohistochemical studies 99  
management 103  
fluid intake 79, 222  
posterior tibial nerve stimulation 81–2  
symptoms 6–7, 62  
day-by-day changes 7  
management 79  
treatment, physical 222  
*see also* detrusor overactivity (DO)
- Overactive Bladder Questionnaire 66
- oxybutynin 94  
diffusion 93  
and diphenhydramine compared 94  
efficacy 92  
muscarinic receptor selectivity 93  
side-effects 197  
trials 90–1  
*see also* intravesical oxybutynin
- oxytocin, secretion 42–3
- pad tests 69
- PAF *see* pure autonomic failure (PAF)
- PAG *see* periaqueductal gray (PAG)
- pain  
abdominal 32–3  
bladder 8  
chronic neuropathic 275  
*see also* back pain
- pallidotomy 176–7
- papaverine, in erectile dysfunction treatment 160
- paracentral lobule 172
- paradoxical sphincter contraction on defecation (PSCD)  
*see* anismus
- paralytic ileus, incidence 189
- parasympathetic innervation, anatomy 27–8
- paraventricular nucleus (PVN) 42  
anatomy 42–3  
rat studies 43  
roles, in sexual drive 42
- parietal lobe 172  
and sexual behavior 172  
and sexual functions 45–6
- Parkinson's disease (PD) 187–200  
anorectal videomanometry 191, 215  
studies 190–1  
antimuscarinics in 94  
and benign prostatic hyperplasia 192  
bladder control, brain structures 195  
and bladder dysfunctions 192–8  
bladder symptoms  
future treatments 198  
investigations 196–7  
management 196–7  
pathophysiology 194–5  
pharmacotherapy 197  
prevalence 193  
treatment 195–6  
and bowel dysfunction 187–92  
pharmacotherapy 191–2  
bowel symptoms, prevalence 189  
and colonic transit time 33

- colonic transit time, studies 190  
and constipation 187, 189  
with dementia 197  
and detrusor overactivity 194–5  
differential diagnosis 206, 210–11, 294  
disease progression 187  
and dopamine dysregulation syndrome 200  
and enteric nervous system 189  
and erectile dysfunction 198  
Hoehn and Yahr staging 189, 193, 200  
and hyperprolactinemia 198  
and hypersexuality 176–7  
and impulse control disorders 200  
lower gastrointestinal tract symptoms 189  
motor symptoms 187  
and multiple system atrophy, differential diagnosis 193  
and nocturia 195, 197  
nocturnal polyuria 63  
non-motor symptoms, assessment 193  
pelvic organ dysfunctions 187  
prevalence 25  
and quality of life 188, 200  
sacral neuromodulation in 198  
and sexual behavior 198–200  
sexual dysfunction in 198–200  
prevalence 198–200  
treatment 200  
sexual functions 199  
sphincter electromyography studies 190–1  
treatment, targets 187  
urine storage disorders 194  
voiding symptoms, incidence 197
- Patient Reported Outcome Measures (PROMs)  
applications 66  
lower urinary tract dysfunction 66
- patients *see* neurological patients;  
post-stroke patients
- Patient's Global Impression of Change 225
- Pausinystalia yohimbe* (tree) 161, 232
- PCOs (polycystic ovaries) 297
- PD *see* Parkinson's disease (PD)
- PDE5 inhibitors *see* phosphodiesterase type 5 (PDE5) inhibitors
- PDE inhibitors *see* phosphodiesterase (PDE) inhibitors
- PEC (percutaneous endoscopic colostomy) 148
- pedophilia 173–4
- pelvic floor 25  
anatomy 25  
males 26
- pelvic floor dysfunction, and spina bifida 256
- pelvic floor muscles (PFMs) 80  
precontraction 80  
strength training 80  
therapeutic electrical stimulation 81  
training, in detrusor overactivity 80
- pelvic floor therapy 79–81  
biofeedback 81  
in erectile dysfunction 160–1  
initial assessment 79–80  
in multiple sclerosis 222  
physical examinations 80  
females 80  
males 80  
in sexual dysfunction, females 162  
therapeutic electrical stimulation 81  
treatments 80–2  
plans 80
- pelvic masses 67
- pelvic nerve injury 278, 282–3  
and bladder dysfunctions 282
- pelvic organ dysfunction  
after cauda equina damage 266  
and cauda equina syndrome 272–3  
management, algorithms 307  
and neuromuscular disorders 278  
and quality of life 188, 207  
questionnaires 312–19  
surveys 312–19
- pelvic organs  
female, and hysterectomy 55  
neural control of 167
- pelvic surgery, autonomic nerve damage 282, 281
- penile erection  
apomorphine induction 43  
improvement 160  
and lower lumbar spine injury 52  
mechanisms 41, 159  
psychogenic 41, 52  
reflexive 41, 52  
neurotransmitters in 159  
pathways 41  
vasodilators 41  
*see also* erectile dysfunction (ED)
- penile innervation 53
- penile prostheses 160, 250
- penile sensation
- lack of, in spina bifida 261  
loss of 157
- penilo-cavernosus reflex 73, 271  
abnormalities 156  
mechanisms 73  
testing 274
- penis  
and brain activation 172  
cortical representation of 45–6  
dorsal nerve 54, 73  
distribution patterns 54  
primary sensory cortex representation 46  
stimulation 51–2
- percutaneous endoscopic colostomy (PEC) 148
- percutaneous nerve evaluation (PNE) 303
- pergolide 195–6, 200
- periaqueductal gray (PAG) 2, 11, 172  
bladder information 12  
control circuits 16  
roles 11–12  
in defecation 30–1  
stimulation 45
- perineo-detrusor inhibitory reflex 80
- perineum, cutaneous sensory innervation 285
- peripheral control  
of micturition 1–2  
changes in bladder disease states 5–9
- peripheral innervation, and sexual functions 53
- peripheral neuropathy, and diabetes mellitus 278
- peristalsis  
colonic-induced 30  
mechanisms 29–30
- Peristeen system 147, 262
- PET *see* positron emission tomography (PET)
- PFMs *see* pelvic floor muscles (PFMs)
- pharmacotherapy  
bladder symptoms, in Parkinson's disease 197  
bowel dysfunction, in Parkinson's disease 191–2  
detrusor overactivity 89–103, 195–6  
detrusor sphincter dyssynergia 104, 249  
neurogenic bladder dysfunctions 89–104



## Index

- pharmacotherapy (cont.)  
neurogenic detrusor overactivity 89–103, 247
- phasic rectal contraction, weak spontaneous 214
- phentolamine, in erectile dysfunction treatment 160
- phenylpropanolamine, in sphincter functional improvement 104
- phosphodiesterase (PDE) inhibitors  
clinical efficacy 97  
mechanisms 96–7  
in neurogenic detrusor overactivity treatment 96–7
- phosphodiesterases 41
- phosphodiesterase type 5 (PDE5) inhibitors  
contraindications 159  
efficacy 158–9  
in erectile dysfunction treatment 158, 217, 250,  
mechanisms 158–9  
side-effects 159
- physically disabled, fecal impaction and 142
- pituitary adenomas 175  
brain imaging 174  
computed tomography brain scans 174
- PLISSIT model 154–5, 235
- PMC *see* pontine micturition center (PMC)
- PNE (percutaneous nerve evaluation) 303
- PNTML (pudendal nerve terminal motor latency) 73, 286
- polycarbofil 191
- polycystic ovaries (PCOs) 297
- polyethylene glycol 191, 214  
laxatives 146
- polyuria 197  
treatment 247  
*see also* nocturnal polyuria
- pontine defecation center 178
- pontine micturition center (PMC) 2, 178  
control circuits 16  
functional brain imaging studies 12  
inhibitory mechanisms 194  
roles 11–12
- pontine tumors, and urinary retention 177
- porphyria 278, 287–8
- positron emission tomography (PET) applications 12  
bladder studies 194  
orgasm studies 49  
sacral neuromodulation studies 300–1, 302
- post-ejaculation, functional brain imaging 50
- posterior fossa tumors, and voiding symptoms 177
- posterior tibial nerve stimulation, for overactive bladder 81–2
- postganglionic fibers 1
- postmenopausal low libido, studies 161
- post-micturition residual volume *see* post-void residual volume (PVR)
- post-stroke patients  
constipation 179–80  
and sexual intercourse 180
- postural hypotension 210–11  
treatment 212
- post-void residual volume (PVR) 271  
definition 69  
measurement 69, 223  
bladder scans 64  
and multiple system atrophy 208
- Pott's disease 271
- PPMS (primary progressive multiple sclerosis), prevalence 220
- prazosin, effects on detrusor overactivity 96
- prefrontal cortex  
activation 15  
and bladder control 14–15  
studies 14–15  
medial, and bladder filling 16  
roles 14
- prefrontal lobotomy, and sexual behavior 172
- preganglionic parasympathetic fibers 1
- pregnancy, and spinal cord injury 251–2
- pressure flow studies, bladder 70–1
- primary progressive multiple sclerosis (PPMS), prevalence 220
- primary sensory cortex, representation of penis 46
- primates, sexual responses 40
- PRMS (progressive relapsing multiple sclerosis), prevalence 220
- procainamide 288
- progressive relapsing multiple sclerosis (PRMS), prevalence 220
- prolactin, inhibition 200
- prolapse, and spinal cord injury 246
- PROMs *see* Patient Reported Outcome Measures (PROMs)
- propiverine 181  
efficacy 92  
trials 92
- prostaglandin E1  
administration issues 231  
in erectile dysfunction treatment 160
- prostate  
laparoscopic views 122  
malignancy testing 68
- prostate cancer, surgery 193
- prostatectomy, and sexual dysfunction 283
- prostate disease  
in aging males 192  
screening 192  
surgery 192–3
- prostate-specific antigen (PSA) 68  
screening 192
- prostheses, penile 160, 250
- PSA *see* prostate-specific antigen (PSA)
- PSCD *see* anismus
- pseudoephedrine, in sphincter functional improvement 104
- psychotherapy, sexual dysfunction 162
- psyllium 191
- puborectalis  
anatomy 26  
functions 26
- pudendal nerve, anatomy 284, 6
- pudendal nerve terminal motor latency (PNTML) 73, 286
- pudendal neuralgia 73, 284–6  
diagnosis 286  
Nantes criteria 286  
etiology 284  
prevalence 284  
symptoms 284–6  
treatment 286

- pudendal somatosensory evoked potentials 73  
 abnormalities 156  
 punch-drunk syndrome 175  
 pure autonomic failure (PAF) 282  
 and bladder dysfunctions 282  
 purinergic pathway, changes 5–7  
 purinergic receptors 3  
 P2X<sub>3</sub>, levels 6–7  
 PVN *see* paraventricular nucleus (PVN)  
 PVR *see* post-void residual volume (PVR)  
 pyridostigmine 211  
 QoL *see* quality of life (QoL)  
 QST (quantitative sensory testing) 231  
 quadriplegia  
 and mouth-cecum transit time 33  
 urethral sphincter stents in 121  
 and vesicoureteric reflux 246  
 quadruped man 268  
 quality of life (QoL)  
 and fecal incontinence 128  
 in lower urinary tract dysfunction 66  
 and multiple system atrophy 206  
 and neurogenic bowel dysfunction 138–9, 149  
 and Parkinson's disease 188, 200  
 and pelvic organ dysfunction 188, 207  
 questionnaires 66  
 and spinal cord injury 128, 241  
 Qualiveen 66  
 quantitative sensory testing (QST) 231  
 quaternary amines 93  
 quebracho, efficacy 161  
 Queen Square algorithm 304  
 questionnaires  
 for lower urinary tract symptoms 66  
 for quality of life 66  
 rACC (rostral anterior cingulate cortex), roles 31–2  
 RAIR *see* recto-anal inhibitory reflex (RAIR)  
 rats, ejaculation studies 52–3  
 Raz, S. 295  
 recto-anal inhibitory reflex (RAIR) 35  
 and fecal incontinence 35  
 measurement 34  
 mechanisms 35  
 roles 35  
 recto-anal videomanometry *see* anorectal videomanometry  
 rectocolic reflex 30  
 rectum, functions 25  
 relapsing remitting multiple sclerosis (RRMS), prevalence 220  
 renal failure, and spinal cord injury 244  
 renal function, assessment 243  
 renal stones, and spinal cord injury 244  
 resiniferatoxin (RTX) 6, 9  
 applications 225  
 intravesical therapy 99  
 mechanisms 89  
 natural sources of 98  
 potency 98  
 retropubic space, laparoscopic views 122  
 rhombencephalitis, magnetic resonance imaging 175  
 Rigiscan 180  
 Riley-Day syndrome *see* familial dysautonomia (FD)  
 rodents, sexual responses 40  
 Rome criteria, modified 32  
 rostral anterior cingulate cortex (rACC), roles 31–2  
 routines, in neurogenic bowel dysfunction management 143  
 Royal College of Anaesthetists (UK) 269–70  
 RP (anal resting pressure) 34  
 RRMS (relapsing remitting multiple sclerosis), prevalence 220  
 RTX *see* resiniferatoxin (RTX)  
 sacral anterior root stimulation with sacral de-afferentation 114–15, 116  
 extradural implantation 115  
 follow-up 115  
 intrathecal implantation 115  
 mechanisms 114–15  
 results 115  
 in spinal cord injury 248  
 surgical technique 115  
 sacral anterior root stimulator (SARS) 148–9  
 sacral dermatomes 268  
 sacral nerve stimulation (SNS) 149  
 applications 10  
 sacral neuromodulation (SNM) 113–14  
 applications 113  
 in chronic urinary retention 303–5  
 complications 114  
 in detrusor sphincter dyssynergia 114  
 development 113  
 efficacy 113–14, 303  
 mechanisms 113, 300  
 in multiple sclerosis 114, 226  
 in Parkinson's disease 198  
 positron emission tomography studies 300–1, 302  
 results 114  
 in spina bifida 114, 262  
 in spinal cord injury 114, 248  
 surgical technique 113  
 in urinary retention  
 outcomes 303  
 patient selection 304–5  
 and voiding 301  
 sacral parasympathetic nucleus (SPN) 4, 10  
 sacral posterior rhizotomy 115, 116  
 sacral root injury 273, 295  
 St Mark's electrodes 73  
 St Mark's scores 128  
 SARS (sacral anterior root stimulator) 148–9  
 Sativex 97, 225  
 SCA (spinocerebellar ataxia), differential diagnosis 206  
 scheduled voiding 79  
 Schwann cells, proliferation 278–9  
 schwannomas 270–1  
 SCI *see* spinal cord injury (SCI)  
 sciatica 270–1  
 scintigraphy 134–5  
 SCOPE *see* Spinal Cord Outcomes Partnership Endeavor (SCOPE)  
 SD *see* sexual dysfunction (SD)  
 secondary progressive multiple sclerosis (SPMS), prevalence 220  
 segmental phasic contractions 29  
 self-stimulation, electrical 176  
 sensory homunculus 46  
 sensory loss, and cauda equina syndrome 272  
 sensory neuropeptides, occurrence 3  
 sensory testing, sexual dysfunction 156–7

## Index

- septum pellucidum, and subcortical lesions 174–5
- serotonergic pathways, mechanisms 198
- serotonin (5-HT) 27  
and sexual reflexes 42
- serum creatinine 68
- serum cystatin C 68
- sex aids 161, 232
- sexual activity  
females 40  
functional brain imaging 46–50
- sexual behavior  
and cerebrovascular disease 180  
and dementia 181  
and focal frontal lesions 172  
and head injuries 181–2  
and parietal lobe 172  
and Parkinson's disease 198–200  
and prefrontal lobotomy 172  
and stroke 180  
and subcortical lesions 176  
animal studies 176  
and temporal lesions 172  
and temporal lobe epilepsy 45, 173
- Sexual Compulsivity Scale 156, 318
- sexual desire, functional brain imaging 47
- sexual development, and spina bifida 260
- sexual deviations 173–4
- sexual drive  
determinants 42, 43  
hemispherical asymmetry 45
- sexual dysfunction (SD)  
blood tests 156  
and cauda equina syndrome 274  
management 275  
classification 153–4  
co-morbidities 157–8, 230  
counseling 162  
and cystectomy 283  
and depression 158  
and diabetes mellitus 280  
drug effects 158  
and epilepsy 45  
evaluation 154–6  
algorithms 308  
patient attitudes 154–5  
patient history 155  
questionnaires 156  
and hysterectomy 283  
laboratory investigations 156–7  
lesion literature for 169  
management, algorithms 308  
multifactorial 155  
and multiple sclerosis 230–5  
diagnosis 231  
disability 231  
healthcare professional roles 235  
investigations 231  
multifactorial causes 230  
pathophysiology 230–1  
prevalence 230  
treatment 230, 231–2  
and multiple system atrophy 214–17  
females 217  
management 217  
in neurological disorders 153–4  
in Parkinson's disease 198–200  
prevalence 198–200  
treatment 200  
pathophysiology  
females 231  
males 230–1  
prevalence 153  
primary 154, 155  
and prostatectomy 283  
psychotherapy 162  
secondary 154, 155  
secondary sources 232  
sensory testing 156–7  
and spasticity 232  
and spina bifida 260–1  
assessment 260–1  
treatment 261  
and spinal cord injury 250–2  
females 251–2  
males 250–1  
surveys 153  
tertiary 154, 155  
tertiary sources 232  
treatment  
approaches 157–8  
females 161–3, 232  
future trends 162–3  
general measures 157–8  
males 158–61, 231–2  
multidisciplinary 153  
outcomes 162  
uro-neurophysiology 156  
use of term 153  
*see also* female sexual dysfunction (FSD); male sexual dysfunction; neurogenic sexual dysfunction
- sexual excitement, functional brain imaging 47–9
- sexual functions  
and amygdala 44–5  
and brainstem 50  
and frontal lobes 45  
future research 56  
neurological control of 40–56  
neurology 56  
and parietal lobe 45–6  
in Parkinson's disease 199  
and peripheral innervation 53  
physiological 153  
physiology 40–1  
rats and humans compared 42–3  
and spinal cord 50  
and temporal lobes 44–5  
and urinary incontinence 162
- sexual intercourse, post-stroke patients 180
- sexuality  
altered 44  
asexuality 173  
*see also* hypersexuality; hyposexuality
- sexual motor behaviors 45
- sexual reflexes, serotonin and 42
- sexual rehabilitation, in spinal cord injury 251
- sexual responses  
animal studies 40  
female 41  
male 41  
phases 41  
primates 40  
rodents 40  
and spinal cord 51  
*see also* human sexual responses
- sexual stimulation  
brain activity patterns 4  
nitric oxide release 159
- sexual symptoms, and multiple system atrophy 214–17
- SF (Short-Form) Qualiveen 66, 314
- sheaths 86
- SIADH (syndrome of inappropriate secretion of antidiuretic hormone) 175
- SIDP (subacute inflammatory demyelinating neuropathy) 280
- sildenafil 200  
efficacy 159  
in erectile dysfunction treatment 158, 160, 217, 231, 261  
in female sexual dysfunction treatment 161, 251  
side-effects 217  
trials 232

- silodosin, effects on detrusor overactivity 96
- single photon emission computed tomography (SPECT)  
applications 12, 207–8  
dopamine transporter studies 193
- Siroky nomogram 70
- slings 121
- small intestine, roles 25
- SNARE proteins 100, 101
- SNM *see* sacral neuromodulation (SNM)
- SNS *see* sacral nerve stimulation (SNS)
- social brain, concept of 167
- social control, of voiding 17–19
- social inhibition, loss of 172
- sodium bicarbonate suppositories 145
- sodium citrate/sorbitol enemas 145–6
- solabegron, in detrusor overactivity treatment 96
- solifenacin, diffusion 93
- somatostatin 27
- spasticity 257  
and sexual dysfunction 232
- SPCs *see* suprapubic catheters (SPCs)
- specialist investigations  
indications 66  
in neurogenic bladder dysfunctions 69
- SPECT *see* single photon emission computed tomography (SPECT)
- sphincter  
botulinum neurotoxin for 104  
functional improvements,  
pharmacotherapy 104, 249  
relaxation 194–5  
*see also* anal sphincter complex;  
detrusor sphincter dyssynergia (DSD);  
urethral sphincter
- sphincter denervation 273, 295
- sphincter electromyography  
neurogenic changes, in multiple system atrophy 209–10  
Parkinson's disease studies 190–1
- sphincterotomy 120
- sphincter relaxation, uninhibited 179
- sphincter surgery 120–1
- sphincter weakness 210  
and multiple system atrophy 213–14
- spina bifida 255–63  
and bladder dysfunctions 256  
and bowel dysfunction 256, 261–2  
assessment 261  
treatment 261–2  
co-morbidities 257  
definition 255  
and fecal incontinence 257, 261  
treatment 262  
fetal surgery 257  
folic acid supplementation 255–6  
mixed dysfunctional patterns 257  
and neurogenic bladder dysfunctions 257  
and neurogenic detrusor overactivity, botulinum neurotoxin type A intradetrusor injections 258, 260  
pathogenesis 255–7  
and pelvic floor dysfunction 256  
penile sensation, lack of 261  
prevalence 25, 255  
risk factors 255  
sacral neuromodulation in 114, 262  
and sexual development 260  
and sexual dysfunction 260–1  
assessment 260–1  
treatment 261  
symptoms 255  
and tethered cord syndrome 262  
types of 256  
and urinary incontinence 257  
and urinary tract dysfunctions 257–60  
assessment 257–8  
surgical treatments 260  
treatment 258  
use of term 255
- spina bifida aperta 255
- spina bifida occulta 255
- spinal canal ependymomas 271
- spinal canal stenosis, and cauda equina syndrome 271
- spinal control, of bladder function 9–11
- spinal cord  
central pattern generators 50–1  
development 266  
normal 256  
formation 255  
and sexual functions 50  
and sexual responses 51
- spinal cord injury (SCI) 241–52  
and autonomic dysreflexia 242–3  
and bladder augmentation 248–9
- and bladder cancer 246
- and bladder dysfunctions 241–9  
chronic phase 242  
assessment 243–4  
investigations 243–4  
follow-up 249  
spinal shock phase 241  
treatment 247
- and bladder stones 244
- and bladder symptoms 242–3  
and bowel dysfunction 32, 249–50
- bowel function  
outcome measures 134  
studies 128  
classification 241  
and colonic transit time 33  
co-morbidities 127  
and compliance 36  
and constipation 32  
and defecation 36  
and detrusor sphincter dyssynergia 242  
and ejaculation 250–1  
epidemiology 241  
and erectile dysfunction 160, 250  
etiology 241  
and fertility 251  
and incomplete bladder voiding 242  
infrasacral lesions 242  
international standards 128  
and kidney stones 244  
life-expectancy 241  
and neurogenic bowel dysfunction 138, 139  
and neurogenic detrusor overactivity 243–4, 245  
and orgasm 251  
and pregnancy 251–2  
prevalence 25  
and prolapse 246  
and quality of life 128, 241  
remaining autonomic functions,  
international standards 128  
and renal failure 244  
and renal stones 244  
sacral anterior root stimulation  
with sacral de-afferentation  
in 248  
sacral neuromodulation in 114, 248  
and sexual dysfunction 250–2  
females 251–2  
males 250–1  
sexual rehabilitation 251  
suprasacral lesions 242  
and ureteric reflux 244  
and urinary frequency 242  
and urinary incontinence 242  
urinary tract complications 244–6  
and urinary tract infections 244

## Index

- spinal cord injury (SCI) (cont.)  
and urinary urgency 242  
and vaginal lubrication 251  
*see also* tethered cord syndrome
- spinal cord lesions 11
- Spinal Cord Outcomes Partnership  
Endeavor (SCOPE) 134  
recommendations 243
- spinal defects, occurrence 256
- spinal fracture, and cauda equina  
syndrome 267
- spinal reflexes  
and bladder pathophysiology 10  
forebrain activation 43
- spinal stenosis 271
- spinocerebellar ataxia (SCA),  
differential diagnosis 206
- SPMS (secondary progressive multiple  
sclerosis), prevalence 220
- SPN (sacral parasympathetic  
nucleus) 4, 10
- SQ (anal squeeze pressure) 34
- stomach, roles 25
- stoma formation 148
- stones  
kidney 244  
*see also* bladder stones
- stools *see* feces
- storage symptoms, in lower urinary  
tract dysfunction 62
- straining, and defecation 30, 191
- strength training, pelvic floor  
muscles 80
- stress tests 67
- stress urinary incontinence  
assessment 67  
management 121–3  
pad tests 69  
symptoms 63–4  
therapeutic electrical stimulation 81
- striatum, electrical stimulation 194
- stroke  
acute hemispheric 179  
and bowel dysfunction 179–80  
and erectile dysfunction 180  
and fecal incontinence 180  
prevalence 25  
and sexual behavior 180  
*see also* post-stroke patients
- subacute inflammatory demyelinating  
neuropathy (SIDP) 280
- subcortical disorders 167–82
- subcortical inputs  
to human sexual cycle 42–3  
animal studies 42
- subcortical lesions 174–6  
and bladder 176  
and bowel 176  
and hypothalamus 174–5  
and septum pellucidum 174–5  
and sexual behavior 176  
animal studies 176
- submucosal plexus 26, 27
- substance, P. 6, 27  
occurrence 3
- suburothelium 3–5, 90
- suppositories 145–6  
efficacy 146  
types of 145
- suprapubic catheterization 83–4  
advantages 84
- suprapubic catheters (SPCs) 122–3  
advantages 122  
applications 249  
contraindications 122  
long-term usage issues 122–3
- suprapubic vibrators, and detrusor  
overactivity 224
- suprasacral injuries, bladder  
dysfunctions in 247
- suprasacral lesions, in spinal cord  
injury 242
- supraspinal network, functions 11
- surgical treatments  
in multiple sclerosis 226–7  
neurogenic bladder dysfunctions  
112–23  
pelvic 281, 282  
in spina bifida 257, 260  
urge incontinence 227
- Swedish Pharmaceutical Insurance 270
- sympathetically mediated reflex 9
- sympathetic innervation 1–2  
anatomy 28–32
- symptom scales  
for neurogenic bladder  
dysfunction 66–7  
for urinary disorders 66–7
- syndrome of inappropriate secretion of  
antidiuretic hormone  
(SIADH) 175
- tadalafil  
efficacy 159, 231
- in erectile dysfunction treatment  
158, 217
- tamsulosin  
applications 211  
effects on detrusor overactivity 96  
trials 96, 104  
vs placebo 96
- tegaserod, applications 192
- temporal lesions, and sexual  
behavior 172
- temporal lobectomy, epilepsy 173
- temporal lobe epilepsy (TLE)  
and asexuality 173  
and hyposexuality 44–5, 173  
and neuroendocrine  
disorders 45  
and sexual behavior 45, 173
- temporal lobe resection (TLR)  
and hypersexuality 173  
outcomes 171
- temporal lobes  
libidinous 172  
roles 172–3  
and sexual functions 44–5
- tenia coli 25
- tertiary amines 93
- testosterone  
assays 156  
deficiency 198  
exogenous transdermal 161
- tethered cord syndrome 262–3  
definition 262  
etiology 262  
and fecal incontinence 263  
and spina bifida 262  
symptoms 262–3
- THC (delta-9-tetrahydrocannabinol),  
applications 225
- therapeutic electrical stimulation  
in detrusor overactivity treatment 81  
pelvic floor muscles 81  
in pelvic floor therapy 81  
stimulation parameters 81  
in stress urinary incontinence  
treatment 81
- tibolone, efficacy 161
- TLE *see* temporal lobe epilepsy (TLE)
- TLR *see* temporal lobe resection (TLR)
- toileting  
and dementia 181  
timing 79
- tolterodine 197

- diffusion 93  
efficacy 89, 92  
trials 90–1
- tramadol 301–2
- transanal irrigation 147
- transient receptor potential menthol 8 (TRPM8) 3
- transient receptor potential (TRP)  
receptor antagonists 97  
roles 97
- transient receptor potential vanilloid 1 (TRPV1)  
activation 3  
antibodies 6  
depletion 99  
expression 97, 98  
levels 7  
receptors 5  
regulatory mechanisms 3  
roles 3
- transient receptor potential vanilloid 4 (TRPV4), roles 97
- transurethral resection of the prostate (TURP), indications 193
- transverse myelitis 235  
studies 235
- Treponema pallidum* (bacterium)  
283–4
- tropium 197  
diffusion 93  
efficacy 92
- TRPM8 (transient receptor potential menthol 8) 3
- TRP receptor antagonists *see* transient receptor potential (TRP) receptor antagonists
- TRPV1 *see* transient receptor potential vanilloid 1 (TRPV1)
- TRPV4 (transient receptor potential vanilloid 4), roles, 97
- TTR* gene, mutations 286
- tuberculosis, and cauda equina syndrome 271
- tumors  
pontine 177  
posterior fossa 177  
resection 271  
*see also* brain tumors; frontal lobe tumors; pituitary adenomas
- TURP (transurethral resection of the prostate), indications 193
- UDI-6 (Urogenital Distress Inventory) 66, 312
- ultrasound scans  
in spinal cord injury 243  
in upper urinary tract damage investigations 69
- UPP *see* urethral pressure profile (UPP)
- upper motor neuron lesions, concept of 294
- upper urinary tract damage  
risk factors, in multiple sclerosis 223  
symptoms 65  
ultrasound scans 69
- upper urinary tract function, preservation 258
- urapidil, trials 104
- ureteric reflux, and spinal cord injury 244
- urethra, functional brain imaging studies 12
- urethral catheterization 83–4
- urethral pressure profile (UPP) 72  
Fowler's syndrome 298
- urethral sphincter  
electromyography 298  
external 210  
internal 208  
striated 296  
and voiding dysfunction 65
- urethral sphincter stents 120  
complications 120–1  
development 120  
permanent 120, 121  
temporary 120, 121
- urethral sphincter-to-bladder inhibitory reflex, activation 10
- urethroscopy 293
- urge-frequency syndrome  
*see* overactive bladder (OAB)
- urge incontinence  
and bladder filling 14  
females 17  
surgery 227
- Urge Incontinence Impact Questionnaire 66
- urgency 13–14  
definition 6  
pathophysiology 6–7  
*see also* urinary urgency
- urgency incontinence 62
- urgency urinary incontinence, symptoms 63–4
- urge syndrome *see* overactive bladder (OAB)
- Urge Urological Distress Inventory 66
- urinals, hand-held 87
- urinalysis  
risk factors 223  
*see also* dipstick urinalysis
- urinary disorders  
and acute hemispheric stroke 179  
symptom scales 66–7
- urinary diversion, and indwelling catheters 227
- urinary frequency 62, 271  
and spinal cord injury 242
- urinary incontinence  
and acute stroke 179  
and Alzheimer's disease 180  
appliances for 85–7  
absorbent 86  
males 86  
and cauda equina syndrome 273  
definition 63  
and dementia 180  
and dementia with Lewy bodies 180  
differential diagnosis 64  
and frontal lobe tumors 171  
and hydrocephalus 171  
and lower urinary tract dysfunction 63  
mixed 63–4  
and multiple sclerosis 221  
and multiple system atrophy 206  
overflow 63–4  
and sexual functions 162  
and spina bifida 257  
and spinal cord injury 242  
urgency 63–4  
urodynamics 259  
and white matter lesions 171  
*see also* stress urinary incontinence
- urinary infections 271
- urinary retention 175, 293–305  
acute complete 293  
antimuscarinics and 90  
and cauda equina syndrome 272, 273  
and cerebrovascular disease 179  
clean intermittent self-catheterization in 297–8  
clinical investigations 297–8  
complete 293, 296  
Queen Square algorithm 304  
etiology 293–303  
structural 293

## Index

- urinary retention (cont.)  
 females 17, 295, 297  
 and focal frontal lesions 171  
 investigations 297–8  
 males 295  
 mechanisms 298  
 and neurological dysfunction 293–5  
 opiate studies 303  
 partial 293  
 pathogenesis 298–301  
 and pontine tumors 177  
 sacral neuromodulation  
 outcomes 303  
 patient selection 304–5  
 treatment 10  
*see also* chronic urinary retention
- Urinary Symptom Profile (USP)  
 66, 314  
 coverage 66
- urinary symptoms  
 and brainstem lesions 177–8  
 and brain tumors 171  
 and cauda equina syndrome 273–4  
 and multiple system atrophy  
 206, 211  
 surveys 212  
 prevalence, and multiple system  
 atrophy 212
- urinary tract complications, in spinal  
 cord injury 244–6
- urinary tract dysfunctions 15  
 and spina bifida 257–60  
 assessment 257–8  
 surgical treatments 260  
 treatment 258  
*see also* lower urinary tract  
 dysfunction (LUTD)
- urinary tract infections (UTIs)  
 and botulinum neurotoxin 102–3  
 dipstick urinalysis 63, 67–8, 223  
 and indwelling catheters 83–4  
 mid-stream urine test 68  
 recurrent 122, 227  
 risk reduction 82  
 and spinal cord injury 244
- urinary tract reconstructive surgery  
 115–17
- urinary urgency 194–5  
 and multiple system atrophy 206  
 and spinal cord injury 242
- urine  
 flow rate, nomograms 70  
 residual, and bladder dysfunction 82  
 withholding of, peak activation  
 areas 13
- urine bags 85
- urine cytology 68
- urine dipsticks *see* dipstick urinalysis
- urine drainage bags, for indwelling  
 catheters 84–5
- urine storage 4, 13, 61  
 disorders, in Parkinson's disease 194  
 mechanisms 10  
*see also* bladder storage
- urine testing, in multiple sclerosis 223
- urodynamics 177–8  
 applications 70–1  
 bladder filling and voiding 70–1  
 in diabetes mellitus 279  
 in multiple sclerosis 223  
 in neurogenic bladder dysfunctions  
 69–71  
 non-compressive myelopathies  
 233, 235  
 in spina bifida 257–8  
 in urinary incontinence 259  
 use of term 223  
*see also* videourodynamics
- uroflow curves, familial amyloid  
 polyneuropathy 287
- uroflowmetry 70  
 for voiding functions 65
- Urogenital Distress Inventory  
 (UDI-6) 66, 312
- uro-neurophysiology  
 neurogenic bladder dysfunctions 72–3  
 sexual dysfunction 156
- urothelial cells 6
- urothelial dysfunction 278–9
- urothelium 3–5, 90  
 roles 7
- USP *see* Urinary Symptom Profile  
 (USP)
- UTIs *see* urinary tract infections (UTIs)
- vacuum constriction devices (VCDs)  
 159–60  
 in erectile dysfunction treatment  
 231–2, 250
- vacuum devices (sex aids) 161
- vaginal atrophy 161
- vaginal lubricants 161, 232
- vaginal lubrication, and spinal cord  
 injury 251
- valproic acid 255
- Valsalva maneuver 26, 30, 67, 82,  
 191, 249, 295
- vanilloid pathway, changes 5–7
- vanilloids (intravesical) *see* intravesical  
 vanilloids
- ildenafil  
 efficacy 159, 231  
 in erectile dysfunction treatment  
 158, 217
- variegate porphyria (VP) 287–8
- vasoactive intestinal peptide (VIP) 27  
 roles 41
- vasopressin, secretion 42–3
- VCDs *see* vacuum constriction  
 devices (VCDs)
- VCMGs (video-cystometrograms) 243–4
- ventral tegmental area (VTA)  
 ejaculation studies 52–3  
 orgasm studies 49–50
- ventriculoperitoneal shunts 176
- vertebrae, numbering systems 266
- vertebral column, formation 255
- vesico-ureteric reflux, and  
 quadriplegia 246
- Viagra *see* sildenafil
- vibrators  
 Ferticare 250–1  
 sex aids 161, 232  
 suprapubic 224
- vibratory stimulation 161
- vibro-ejaculation 250–1
- video-cystometrograms (VCMGs)  
 243–4
- videourodynamics  
 applications 71–2  
 bladder filling 65  
 in neurogenic bladder dysfunctions  
 71–2  
 procedures 71–2  
 in spina bifida 257–8
- VIP *see* vasoactive intestinal  
 peptide (VIP)
- visceral enteropathy 295
- voiding  
 frequency/voiding charts 79  
 functions, uroflowmetry 65  
 mechanisms 4  
 motivation 13–14  
 and sacral neuromodulation 301  
 scheduled 79  
 social control of 17–19  
*see also* bladder voiding

Cambridge University Press

978-0-521-19831-8 - Pelvic Organ Dysfunction in Neurological Disease: Clinical Management and Rehabilitation

Edited by Clare J. Fowler, Jalesh N. Panicker and Anton Emmanuel

Index

[More information](#)

## Index

- voiding cystourethrography 257–8
- voiding dysfunction  
  brainstem lesions for 177  
  and brain tumors 177  
  incidence 194  
  management 82  
  clean intermittent self-catheterization  
  82–4, 223–4, 259  
  indwelling catheterization 83, 224  
  and multiple sclerosis, management  
  223–4  
  opiates and 301–3
- and pure autonomic failure 282  
  urethral sphincter and 65
- voiding reflex 11  
  control circuits 11, 16
- voiding symptoms  
  incidence, in Parkinson's disease 197  
  and lower urinary tract dysfunction 65  
  multiple system atrophy 208  
  and posterior fossa tumors 177
- von Frey hairs 157
- VP (variegate porphyria) 287–8
- VTA *see* ventral tegmental area (VTA)
- Wexner scores 128
- white matter lesions, and urinary  
  incontinence 171
- Wolfram syndrome 288
- X-rays, pelvic 113
- Yang-Monti procedure 119
- yohimbine  
  efficacy 161, 232  
  side-effects 232